Xenon Pharmaceuticals
XENE
175 hedge funds and large institutions have $2.36B invested in Xenon Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 57 increasing their positions, 56 reducing their positions, and 20 closing their positions.
68% more call options, than puts
Call options by funds: $5.17M | Put options by funds: $3.07M
65% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 20
8% more capital invested
Capital invested by funds: $2.19B → $2.36B (+$169M)
7% more funds holding
Funds holding: 163 → 175 (+12)
2% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 56
0.52% less ownership
Funds ownership: 97% → 96.48% (-0.52%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$31.9M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$27.2M |
| 3 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$21.8M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$19.1M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$24.8M |
| 2 |
PA
Perceptive Advisors
New York
|
-$24.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$14.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.2M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$13.1M |
XENE Hedge Fund Activity: Q2 2023 in Review
175 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2023, worth a combined $2.36B — up 7.7% from $2.19B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new XENE positions and 20 closed out — a net gain of 13 holders — while 57 added to existing stakes and 56 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $31.9M. The largest seller was Logos Global Management, cutting an estimated $24.8M.
- 175 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2023, up from 163 in Q1 2023.
- Funds reported $2.36B of Xenon Pharmaceuticals stock for Q2 2023, up 7.7% quarter-over-quarter.
- 33 funds opened new Xenon Pharmaceuticals positions in Q2 2023 and 20 closed out, a net change of +13 holders.
- The largest Xenon Pharmaceuticals buyer in Q2 2023 was Wellington Management Group, an estimated $31.9M added.
- The largest Xenon Pharmaceuticals seller in Q2 2023 was Logos Global Management, an estimated $24.8M sold.
Based on aggregated 13F filings for Q2 2023.